Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M.R. Garcia Campelo
PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Brigatinib Bei ALK-positivem NSCLC
Im Focus Onkologie
1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib
Lung Cancer Management
Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient
Molecular and Clinical Oncology
Cancer Research
Oncology
P2.13-03 Real-Life Experience With Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience
Oncotarget
Oncology
P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib
Journal of Community and Supportive Oncology
Oncology
Hematology
